Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 20, 2026Veterinary Anaesthesia and AnalgesiaOpen Access

Effectiveness of dimenhydrinate and maropitant in preventing preoperative emesis and nausea in healthy dogs sedated with hydromorphone and dexmedetomidine: a randomized, blinded trial

View Full Paper
Ask AI
Bookmark
Share

Authors

CSChi Won ShinUniversity of SaskatchewanBABarbara AmbrosUniversity of Saskatchewan

Discussion

Loading...

Member takes

Implication

A randomized trial evaluates anti-nausea effects of dimenhydrinate and maropitant in dogs, indicating mixed effectiveness.

Key Points

  • The study aims to evaluate the effectiveness of dimenhydrinate and maropitant in preventing nausea and vomiting in dogs sedated with hydromorphone and dexmedetomidine.
  • Conducted a randomized, blinded, placebo-controlled clinical trial.
  • Included 87 healthy dogs undergoing ovariectomy/castration.
  • Administered maropitant SC, dimenhydrinate IM, or placebo 60 minutes before premedication.
  • Documented discomfort, nausea, and vomiting post-treatment and analyzed data for statistical significance.
  • Discomfort after injection was significantly higher in the maropitant group compared to the other groups.
  • Nausea incidence rates were not significantly different between treatment groups.
  • Maropitant significantly reduced the incidence of vomiting compared to dimenhydrinate and placebo.
  • Dimenhydrinate did not show any measurable anti-nausea or anti-emetic effects.

Cite This Study

Shin et al. (2026) studied this question.

synapsesocial.com/papers/69e5c36103c2939914029322https://doi.org/10.1016/j.vaa.2026.101235
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Dimenhydrinate for prophylaxis of postoperative nausea and vomiting: a meta‐analysis of randomized controlled trials2002 · 178 citations
  2. 2The pharmacokinetics of maropitant, a novel neurokinin type‐1 receptor antagonist, in dogs2007 · 80 citations